Nature’s Bounty has chosen a retail veteran to join its team as chief communications officer. Amy von Walter, most recently executive vice president of global communications and customer care for Toys “R” Us, will lead the Ronkonkoma, N.Y.-based company’s external and internal communications, as well as its government affairs and corporate social responsibility efforts, reporting to president and CEO Paul Sturman. “Amy is a seasoned communications leader with a proven track record,” Sturman said. “I am confident that her experience, coupled with her energy and collaborative approach, will help us achieve our ambitious goals for growth and further build on the culture here at Nature’s Bounty.”
BioNTech AG, a biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease has entered into a multi-year research and development (R&D) collaboration with Pfizer to develop mRNA-based vaccines for prevention of influenza. “Today’s agreement with Pfizer is one of a number of steps that we are taking to rapidly build a sustainable R&D presence in infectious disease, combining our deep understanding of the immune system to treat disease with the cutting-edge technologies and significant infrastructure that we have built-up over many years to develop immunotherapy treatments,” BioNTech co-founder and CEO Ugur Sahin, said, in a press statement. “A significant presence in infectious disease supports our goal of building a global immunotherapy company that provides more effective and precise immune-mediated approaches for the prevention and treatment of serious illnesses, such as the prevention of flu and the treatment of cancer.”
Lannett announced earlier this week that its distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which expires on March 23, 2019, will not be renewed. “The Steinlauf family advised us this past Friday evening that they will not renew our agreement to distribute three JSP products: butalbital, aspirin, caffeine with codeine phosphate capsules USP, digoxin tablets USP and levothyroxine sodium tablets USP, upon its expiration in March 2019,” Tim Crew Lannett’s CEO, said. “The family has assured us of a continuous supply of the products through March of next year. These products remain valuable assets for us and are expected to significantly contribute to our financial performance in fiscal 2019.
Lupin has received the Food and Drug Administration’s tentative approval for Nudovra (estradiol valerate tablets, 3 mg and 1 mg and estradiol valerate and dienogest tablets, 2 mg/2 mg and 2 mg/3 mg) tablets, an estrogen/progestin combined oral contraceptive, indicated for use by women to prevent pregnancy. The product, which is a generic version of Bayer HealthCare Pharmaceuticals’s Natazia tablets, had a market value of approximately $31.4 million, according to June 2018 IQVIA data.